资讯
1 天
Zacks Investment Research on MSNUltragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAUltragenyx Pharmaceuticals RARE announced that the FDA has issued a Complete Response Letter (CRL) for its biologics license ...
3 天
GlobalData on MSNUltragenyx receives complete response letter for UX111 BLAThe FDA's request stems from observations made during recent inspections of Ultragenyx's manufacturing facilities.
Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...
8 天on MSN
Olivia had been showing symptoms since she was just 7 months old — including a belly that remained swollen, hard to the touch ...
Novato, California Monday, July 14, 2025, 16:00 Hrs [IST] ...
Ultragenyx Pharmaceutical (Nasdaq: RARE) has been dealt a regulatory setback, as the American medicines regulator has ...
2 天
Investor's Business Daily on MSNUltragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A RejectionUltragenyx Pharmaceuticals took another hit when the FDA rejected its gene therapy for patients with a rare, genetic disorder.
Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle bones. The U.S. FDA gave the company a ...
The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果